All In Biotech

Drug Trial Radar · NCT00084266

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus

Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,225

Actual

Start

Oct 2004

Primary completion

Mar 2010

Study completion Mar 2010

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 11, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

Conditions

  • Methicillin Resistant Staphylococcus Aureus (MRSA)

Interventions

  • linezolid (Zyvox)Drug

    Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.

  • vancomycinDrug

    Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP PopulationTime frame: EOS (7-30 days after last dose)

Locations

177 sites in 22 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Huntsville, Alabama

  • Pfizer Investigational Site

    Montgomery, Alabama

  • Pfizer Investigational Site

    Montgomery, Alabama

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Orange, California

  • Pfizer Investigational Site

    Redlands, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Newark, Delaware

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Brandon, Florida

  • Pfizer Investigational Site

    Fort Lauderdale, Florida

  • Pfizer Investigational Site

    Gainesville, Florida

  • Pfizer Investigational Site

    Jackson, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Augusta, Georgia

  • Pfizer Investigational Site

    Augusta, Georgia

  • Pfizer Investigational Site

    Decatur, Georgia

  • Pfizer Investigational Site

    Decatur, Georgia

  • Pfizer Investigational Site

    Honolulu, Hawaii

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    North Chicago, Illinois

  • Pfizer Investigational Site

    Oak Park, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.